secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2022-09-27T23:59:59+00:00
Accession:  0001842952-22-000086
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics extends cash runway to Q1 2024, prioritizes key pipeline programs
--------------------------------------------------------------------------------

- Cash runway extended to Q1 2024; deferring noncritical R&D and reducing overhead.
- ONA-XR ELONA Phase 1b/2 trial with elacestrant for ER+/PR+/HER2- mBCa starts Q4 2022; data Q4 2023.
- CLDN6xCD3 BsMAb candidate nomination Q4 2022; IND submission planned Q1 2024.
- Preliminary data from ISTs: granulosa cell/endometrial cancer Nov 2022; breast cancer Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000086/0001842952-22-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000086/cntx-20220927.htm
  HTML page:      https://secwatch.observer/filing/0001842952-22-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer